keyword
MENU ▼
Read by QxMD icon Read
search

spd476

keyword
https://www.readbyqxmd.com/read/22970981/multi-matrix-system-mmx%C3%A2-mesalamine-for-the-treatment-of-mild-to-moderate-ulcerative-colitis
#1
REVIEW
Sara N Horst, Sunanda Kane
INTRODUCTION: Ulcerative colitis (UC) is an inflammatory disease of the colon characterized by periods of active disease and remission. The pathogenesis of this disease is likely a complex interaction of genetic predisposition, environmental factors, and immune system dysregulation, and is not completely understood. A Multi-MatriX (MMX®) system formulation of mesalamine, MMX mesalamine (SPD476; Lialda®; Mesavancol®; Mezavant®), allows for high-dose, once-daily dosing for patients with mild-to-moderate UC...
October 2012: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/19357797/reformulation-of-an-aminosalicylate-an-example-of-the-importance-of-pill-burden-on-medical-compliance-rates
#2
REVIEW
Mark T Osterman, Gary R Lichtenstein
Ulcerative colitis is an idiopathic chronic inflammatory disease of the colon characterized by symptoms of bloody diarrhea and abdominal pain. Although conventional aminosalicylates have been the foundation of treatment of mild to moderate ulcerative colitis for both the induction and maintenance of remission, they are limited in a number of ways, such as which formulation and what dose are optimal, as well as the high pill burden, which often leads to low compliance with these medications. Multi-Matrix System (MMX) mesalamine (SPD476) is a promising new aminosalicylate formulation; it seems to have solved some of the problems of conventional aminosalicylates, as it is effective as a once-daily treatment in high doses and induces both clinical remission and endoscopic mucosal healing...
January 2009: Methods and Findings in Experimental and Clinical Pharmacology
https://www.readbyqxmd.com/read/18671232/effect-of-extended-mmx-mesalamine-therapy-for-acute-mild-to-moderate-ulcerative-colitis
#3
MULTICENTER STUDY
Michael A Kamm, Gary R Lichtenstein, William J Sandborn, Stefan Schreiber, Kirstin Lees, Karen Barrett, Raymond Joseph
BACKGROUND: Many patients with ulcerative colitis (UC) respond to mesalamine therapy within 8 weeks. Those not achieving remission after 8 weeks are often treated with steroids or other immunosuppressive therapies. This study aimed to determine the effect of 8 weeks' high-dose MMX mesalamine extension therapy in patients with active, mild-to-moderate UC who had previously failed to achieve complete remission in 2 phase III, double-blind, placebo-controlled studies of MMX mesalamine (SPD476-301 and -302)...
January 2009: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/18182473/multi-matrix-system-mesalamine-to-use-or-not-to-use
#4
REVIEW
Pramodini B Kale-Pradhan, Rohan S Pradhan, Sheila M Wilhelm
OBJECTIVE: To evaluate the role of Multi-Matrix System (MMX) mesalamine in the treatment of ulcerative colitis (UC). DATA SOURCES: Literature was obtained through searches of MEDLINE (1966-October 2007) and a bibliographic review of published articles. Key terms used in the searches included ulcerative colitis, mesalamine, MMX, SPD476, and Lialda. STUDY SELECTION AND DATA EXTRACTION: All English-language articles that were identified through the search were evaluated...
February 2008: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/17241860/once-daily-high-concentration-mmx-mesalamine-in-active-ulcerative-colitis
#5
RANDOMIZED CONTROLLED TRIAL
Michael A Kamm, William J Sandborn, Miguel Gassull, Stefan Schreiber, Lechoslaw Jackowski, Todd Butler, Andrew Lyne, David Stephenson, Mary Palmen, Raymond E Joseph
BACKGROUND & AIMS: SPD476 (LIALDA in the US; MEZAVANT in the EU; otherwise known as MMX mesalamine; Shire Pharmaceuticals Inc., Wayne, PA, under license from Giuliani SpA, Milan, Italy) is a novel, once-daily, high-strength (1.2 g/tablet) formulation of mesalamine, utilizing MMX Multi Matrix System (MMX) technology designed to deliver the active drug throughout the colon. We performed a double-blind, multicenter study, comparing MMX mesalamine vs placebo for the treatment of active ulcerative colitis...
January 2007: Gastroenterology
https://www.readbyqxmd.com/read/17234558/effect-of-once-or-twice-daily-mmx-mesalamine-spd476-for-the-induction-of-remission-of-mild-to-moderately-active-ulcerative-colitis
#6
RANDOMIZED CONTROLLED TRIAL
Gary R Lichtenstein, Michael A Kamm, Prabhakar Boddu, Natalya Gubergrits, Andrew Lyne, Todd Butler, Kirstin Lees, Raymond E Joseph, William J Sandborn
BACKGROUND & AIMS: SPD476 (MMX mesalamine), a novel, once-daily mesalamine formulation, uses MMX Multi Matrix System (MMX) technology to delay and extend delivery of active drug throughout the colon. We performed a randomized, double-blind, parallel-group, placebo-controlled, multicenter phase III study in patients with mild to moderately active ulcerative colitis. METHODS: Two hundred eighty patients with mild to moderately active ulcerative colitis received MMX mesalamine 2...
January 2007: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/16984503/once-daily-mmx-mesalazine-for-the-treatment-of-mild-to-moderate-ulcerative-colitis-a-phase-ii-dose-ranging-study
#7
RANDOMIZED CONTROLLED TRIAL
G D'Haens, D Hommes, L Engels, F Baert, L van der Waaij, P Connor, J Ramage, O Dewit, M Palmen, D Stephenson, R Joseph
BACKGROUND: SPD476 (MMX mesalazine), is a novel, once daily, high-strength mesalazine formulation (1.2 g/tablet) that utilizes Multi Matrix System (MMX) technology to delay and extend delivery of the active drug throughout the colon. AIM: To assess the safety and efficacy of MMX mesalazine in patients with mild-to-moderately active ulcerative colitis, in a pilot, phase II, randomized, multicentre, double-blind, parallel-group, dose-ranging study (SPD476-202). METHODS: Thirty-eight patients with mild-to-moderately active ulcerative colitis were randomized to MMX mesalazine 1...
October 1, 2006: Alimentary Pharmacology & Therapeutics
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"